What the FDA labels say about taking them together
Colchicine and fenofibric acid
Colchicine's FDA label of July 22, 2025 names fenofibric acid in its warnings and precautions section, and fenofibric acid's label names colchicine too. The fenofibric acid label: “Cases of myopathy and rhabdomyolysis have been reported with concomitant use of colchicine with fenofibrates.”
Check it at the source: the colchicine FDA label on DailyMed (effective July 22, 2025, Aurobindo Pharma Limited); the fenofibric acid FDA label on DailyMed (effective August 2, 2025, Aurobindo Pharma Limited).
What does the colchicine label say about fenofibric acid?
Colchicine label, warnings and precautionsConcomitant use of atorvastatin, simvastatin, pravastatin, fluvastatin, lovastatin, gemfibrozil, fenofibrate, fenofibric acid or benzafibrate (themselves associated with myotoxicity) or cyclosporine with colchicine may potentiate the development of myopathy [see Drug Interactions (7) ].
Lodoco label (AGEPHA Pharma USA, LLC, August 13, 2026), warnings and precautionsConcomitant use of LODOCO and HMG CoA reductase inhibitors, gemfibrozil, and fenofibric acid or cyclosporine may potentiate the development of myopathy [see Drug interactions (7)].
Source: FDA drug label (Lodoco, NDA215727), AGEPHA Pharma USA, LLC, effective August 13, 2026 (SPL set ff06d68f-d65f-d097-e053-6294a90a7e5f), via openFDA
Source: FDA drug label (Colchicine), Aurobindo Pharma Limited, effective July 22, 2025 (SPL set dd93a40f-92ab-47ac-9083-b8a7a0b18ad6), via openFDA; the full label on DailyMed
What does the fenofibric acid label say about colchicine?
Fenofibric acid label, drug interactionsClinical Impact: Cases of myopathy and rhabdomyolysis have been reported with concomitant use of colchicine with fenofibrates. Intervention: Consider if the benefit of using colchicine concomitantly with fenofibric acid delayed-release capsules outweighs the increased risk of myopathy and rhabdomyolysis. If concomitant use is decided, monitor patients for signs and symptoms of myopathy, particularly during initiation of therapy and …
Fenofibric acid label, warnings and precautionsConsider whether the benefit of using colchicine concomitantly with fenofibric acid delayed-release capsules outweighs the increased risk of myopathy [see Drug Interactions (7) ].
Source: FDA drug label (FENOFIBRIC ACID), Aurobindo Pharma Limited, effective August 2, 2025 (SPL set 9ad201de-fa62-4c49-bc61-ee09b9ba434c), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Colchicine | Fenofibric acid | |
|---|---|---|
| Labeled for | Gout | High cholesterol, High triglycerides |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $0.122 per tablet 0.6 mg tablet | $0.286 per capsule 135 mg capsule |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once